Channels

Innovation Events

event Innovation

Innovation Lounge «Le Tout Connecté»

Date: 28.02.2019

Place: Cinemont, Rue Emile-Boéchat 85, 2800 Delémont

BaselArea.swiss et Raiffeisen ont le plaisir de vous inviter à l’événement
« Le tout connecté 2019 : santé et innovation ». Les échanges et l’utilisation des données s’intensifient, de nouvelles technologies permettent de créer des circuits plus rapides qui offrent de nouveaux modèles d’affaires – avec des opportunités inégalées dans le domaine de la santé. Venez découvrir les évolutions du système de santé et découvrir de nouvelles opportunités d’affaires.

Date: 28.02.2019, 18 :00 – 21 :00
Lieu: Cinemont, Rue Emile-Boéchat 85, 2800 Delémont

 
Programme

17:30

Ouverture des portes

18:00

Mot de bienvenue

Domenico Scala, Président, BaselArea.swiss

Jacques Gerber, Ministre de l’économie et de la santé, Président du Gouvernement, République et Canton du Jura

Stefan Jeker, responsable RAI Lab, Raiffeisen Suisse

18:25

Impulsions sur le thème de la santé connectée

Prof. Dr. mult. Hans-Florian Zeilhofer, Associate Vice-President for Innovation, University of Basel

Victor Callegari, Director Business Development, Turck duotec

19:00

Table ronde et débat

Stefan Jeker, responsable RAI Lab, Raiffeisen Suisse

Prof. Dr. mult. Hans-Florian Zeilhofer, Associate Vice-President for Innovation, University of Basel

Victor Callegari, Director Business Development, Turck duotec

Alain Bindels, Head of Innovation Facilitation et Basel Innovation GroupLead F. Hoffmann-La Roche Ltd

Frank Kumli, Head of Innovation and Entrepreneurship, BaselArea.swiss

19:45

Apéritif dînatoire et réseautage

Modération par Gaetan Vannay, COO SecuraXis, conférencier et formateur, spécialiste sécurité humaine
 
Traduction simultanée en allemand.
 
L’inscription est gratuite mais obligatoire avant le 26.02.2019.
 

event BaselArea.swiss

S.C.O.R.E© Sales Seminar for Entrepreneurs

Date: 03.09.2019

Place: Switzerland Innovation Park Basel Area AG, Gewerbestrasse 24, 4123 Allschwil

event Supporting Entrepreneurs

Seminar Vorbereitung zur Firmengründung

Date: 17.06.2019

Place: Standortförderung Baselland, Amtshausgasse 7, 4410 Liestall

event Innovation

Innovation Lounge «Le Tout Connecté»

Date: 06.03.2018

Place: Cinémont, Rue Emile-Boéchat 85, 2800 Delémont

BaselArea.swiss, Creapole SA et Raiffeisen Suisse ont le plaisir de vous inviter à l’événement « Innovation Lounge » qui aura lieu le 6 mars 2018 à Delémont.
 
Cette manifestation vous amènera, grâce à des impulsions visionnaires, à découvrir de nouvelles voies dans l’innovation et plus particulièrement dans la PME de production connectée et les données de production sécurisées. Cette rencontre s’adresse aux entrepreneurs, patrons de PME et décideurs qui sont intéressés par l’innovation et la thématique « Le Tout Connecté ».
 
Venez nombreux chercher et échanger de nouvelles idées lors de cette
deuxième édition.

 
Programme

17:30  Accueil des invités
18:00 Ouverture par
M. Domenico Scala
Président, BaselArea.swiss
18:10 Introduction par
M. Patrik Gisel
Président de la Direction, Raiffeisen Suisse
18:20 Impulsion sur la PME de production connectée
M. Raphaël Müller
Senior Consultant Industrial Solutions, Brütsch/Rüegger Outils SA
18:40 Impulsion sur les données de production sécurisées
M. René Fell et M. Frans Imbert-Vier
Président, VIGISWISS / Directeur, UBCOM SA
19:00 Table ronde et débat avec les intervenants
19:45 Apéritif dînatoire et réseautage

Modération par M. Gaetan Vannay, COO Securaxis, Conférencier.

 
La connectivité des objets et des machines est devenu, au cours de ces dernières années, un phénomène croissant dans le monde de l’industrie. Les chaînes de production et de valeur se connectent, les entreprises toutes entières traitent des milliers de données. L’industrie 4.0 plonge les entrepreneurs dans des questionnements liés aux opportunités que cela représente, au gain de temps et d’efficacité que cela permet, au retour sur investissement mais également à un risque en terme de sécurité des données. Le secteur des PME de production dans les domaines de la microtechnique, de la machines-outils et les sous-traitants sont concernés par ces questions, tout autant que les PME des autres domaines d’activités. Les intervenants nous apporteront une vision concrète et pratique sur ces sujets et les préoccupations qui y sont liées.
 
L’inscription est gratuite mais obligatoire jusqu’au 05 mars 2018. Les places sont attribuées selon leur ordre d’arrivée.

 

event Supporting Entrepreneurs

Clevere Preisgestaltung für innovative Produkte und Services – Praktische Tipps vom Expert...

Date: 07.05.2019

Place: Switzerland Innovation Park Basel Area AG, Gewerbestrasse 24, 4123 Allschwil

event Supporting Entrepreneurs

Seminar Vorbereitung zur Firmengründung

Date: 11.04.2019

Place: Switzerland Innovation Park Basel Area AG, Gewerbestrasse 24, 4123 Allschwil

Innovation Report

report Supporting Entrepreneurs

"It doesn't always have to stay the same"

08.01.2019

Désirée Mettraux has been the CEO of Creadi since 2016. The Pax spin-off has developed the Simpego online insurance platform. The insurance expert is confident that the industry will profit if it opens itself up to partners. The aim is to make insurance fun.

BaselArea.swiss: Frau Mettraux, what does insurance mean to you?

Désirée Mettraux: For many people, insurance is a boring and complicated topic. I associate insurance with freedom. I want to make insurance fun.

The Pax spin-off was founded in 2016. What has changed since then?

We discarded many of our original ideas. A great deal of progress and development is taking place in the InsurTech market, with a lot of money being invested throughout Europe. We are also seeing which models don’t work in the B2C market. We are critical with ourselves and question our actions regularly. Simpego – our online platform for insurance companies – was developed from a test phase in which we tried out many things.

Creadi is financed by Pax, right?

Exactly. Agile spin-offs are the ideal learning environment for large parent companies. At the same time, they are great for attracting talent. With Simpego, we launched the first native app on the Swiss market in which insurance policies can be taken out “on the go”. Not every insurance company would be able to get an app such as this off the ground so quickly. However, we have been able to work together with a major insurance provider to test how its product works on the platform. Everyone will benefit from the insights gained as part of this test.

How much does the Swiss insurance industry still have to learn in the field of InsurTech?

With 12 percent of insurance policies taken out online, Switzerland is lagging far behind other European countries. This compares with over 30 percent in Germany. Making up this shortfall will not be simple.

Why?

If society is not yet ready to utilise these offerings, it would not make sense for an insurance company to make its products available digitally. Our society still prefers to go down the traditional route with insurance advisors.

Creadi is setting out to turn this model upside down. This might not please everyone.

There have been pioneers who have forced themselves onto the market while not making themselves popular in the process. However, this does the market no harm. When a change is introduced or an innovation is developed, everyone has to respond accordingly. Ultimately, this benefits consumers.

It is obvious that many people trust insurance brokers who can explain the policies in layman terms. How do you develop a sense of trust with an app?

Trust and brand perception are our greatest challenges. Of course, the personal contact that some customers have enjoyed with their insurance agents for decades cannot simply be forgotten. That’s why we offer our customers the possibility of engaging in live chat or of receiving advice by telephone.

Could this be the solution?

In my opinion, we need to shift our focus elsewhere. While most insurance products that don’t deal with the complex area of pensions are standard and no-one is reinventing the wheel when it comes to personal liability insurance, Mobiliar agents only sell their own products, which may not necessarily be what the customer is looking for. We want to solve this problem and offer a different service. Customers should be able to choose with which provider they take out insurance policies online and whether they want to make use of advice. With us, you can take out an insurance policy in a minute, without any paperwork at all.

What feedback have you received from other insurance providers?

There are companies that want nothing to do with InsurTech companies, as they don’t want to weaken their own sales channels. However, there are now an increasing number of insurance providers who are receptive to digitisation issues and want to try out new things. We are, in principle, open to every new partner. I am very much in favour of the whole industry opening up and working together as part of a common ecosystem.

It sounds like a great idea...

... but things are a little different in reality. That’s why we are trying to bring together different providers on our marketplace. It doesn’t always have to stay the same.

What role is digitisation playing in the industry?

Any companies that still carry out manual processes electronically have not yet embraced digitisation. For me, digitisation is an attitude and a matter of placing the customer at the centre of everything we do. Many companies adopt an inside-out approach rather than one looking from the outside in. There’s still a lot to be done in this respect. We all – including insurance providers – need a strategy for a digital world. Who would have thought twelve years ago that we would be buying our shoes and clothes almost exclusively online? Perhaps we will also reach this point with insurance someday.

Do insurance products also need to be modernised and brought in line with the times?

Yes, of course. The younger generation of customers are taking an increasingly hybrid approach to purchases. They buy M-Budget cottage cheese and at the same time FineFood olive oil. We are also seeing this in terms of insurance. While it should be clear to everyone that 25-year-olds have no need for CHF 5,000 of frozen food cover in their household insurance, this item is still a standard component of many household insurance policies. However, if you live in a cheaply furnished shared apartment, for example, you might need an insurance policy to cover a bicycle worth CHF 4,000 or your mobile phone and laptop. Many insurance policies no longer match up with our lifestyles, especially in urban regions.

Another problem is the image.

Insurance companies have the reputation of always wanting to sell you something. Here at Creadi, we want to change this image and create a sense of transparency. If we don’t have the right offering for somebody, we tell them this and point them towards products that suit them better. We also don’t offer long-term contracts; everything is arranged on a short-term basis.

Creadi was presented with the DIAmond Award last year. Congratulations, albeit belatedly!

Thank you. We have programmed the Simpego Snap vehicle registration document scanner. It takes a photo of the vehicle registration document and processes it using image processing before the program subsequently makes an appropriate offer for the type of vehicle. This program is based on a clever algorithm that tells you the types of vehicle coverage available, depending on the model, category and year of registration. This allows customers to take out vehicle insurance in one minute flat. The program is designed for mobile devices, as the vehicle registration document is usually stored in a vehicle’s glove compartment. I think products such as these are great, as they make life simpler.

What do awards such as this one mean to you?

It was important for us that the award validated our product in front of over 1,000 people from the industry. We have proven and confirmed in our industry that we are on the right track. This is a very valuable proposition and facilitates access to other partners. Our development and performance show that we are much more than just an insurance broker.

There are 15 people working at Creadi at the moment. How easy was it to bring new people into the company?

Basel is a difficult place in which to set up a technology startup. Despite this, we made a conscious decision to be based in Basel. Some of our employees moved here especially for us. Basel is certainly an attractive location that has a great deal to offer in terms of culture and infrastructure. The city also has an international flair. Nevertheless, it is of compact size and our employees are able to find affordable housing.

report Precision Medicine

BC Platforms bietet neue Dienstleistungen an

15.01.2019

report BaselArea.swiss

Basel researchers identify drug against the formation of metastasis

14.01.2019

report Precision Medicine

“Momentum for blockchain in healthcare is growing in Basel”

03.12.2018

Marco Cuomo and Daniel Fritz from Novartis got engaged in blockchain two years ago. Today, their aim is set high: With other pharma companies under the Innovative Medicines Initiative, they formed a “Blockchain Enabled Healthcare” program, due to kick off in 2019. The program that they presented at the Blockchain Leadership Summit in Basel – Switzerland’s largest conference in this field - wants no less than to define how blockchain is applied in healthcare.

BaselArea.swiss: You both work for Novartis that is known for pharmaceutical products but not for technology. How come you started to explore the possibilities of Blockchain in the first place?

Marco Cuomo: We got curious about blockchain and wanted to know which problems we can solve with the technology. A handful of interested people had an informal meeting, we formed a group and basically got to the essence of blockchain. That started two years ago.

What did you find?

Marco Cuomo: First of all we found use cases to learn more about it. This is how the supply chain got on our radar because Blockchain is applicable to tracking and tracing. We involved Dan who is our Supply Chain Domain Architect to build a supply chain from the manufacturer to the pharmacy with LEGO robots…

Daniel Fritz: …where we integrated IoT sensors for temperature and humidity as well as a counterfeit product check. We learned for ourselves about the power of blockchain and what is possible.

Marco Cuomo: Our LEGO demo clearly helped to illustrate our point internally as well as externally. We also quickly realized that other pharmaceutical companies must have the same discussions. So we brought other companies to the table.

Why did you not just develop something on your own?

Marco Cuomo: Of course, you can have for example your own cryptocurrency – and then what? To exchange it, you need other parties who use the same cryptocurrency as you do. No, blockchain is not just a new technology that you learn, implement and benefit from. The key feature is to transfer something valuable from one party to the next. Take the supply chain of pharmaceutical products that involves the manufacturer, the distribution center, wholesale, pharmacy, doctor and hospital. Here, blockchain starts to make sense. 

How so?

Marco Cuomo: With blockchain, you do not have to change any supply management system on your side. Instead, you create a kind of common ground. You do not need an intermediate as blockchain is taking that role. We tend to say that it is a team sport because everybody has to play by the same rules.

What is in it for the life sciences industry?

Daniel Fritz: When we show and explain what blockchain is about, we not only cover the basics. Instead, we also look on what we could potentially design as a solution to build upon the regulatory framework. People think, wait, we can even go beyond the law and uncover some business value. I think most people can quickly see that blockchain offers many benefits over the existing technologies that we have in place.

Marco Cuomo: What is in it is efficiency which comes down to saving money, be faster and more secure. Electronic records can be transparently shown in the blockchain. If something fails in the cool chain, everybody can see what happens immediately. Now you wait till a product arrives at the target to then find out that it is flawed and finally start the process for a resend. With blockchain the flawed product never even has to leave the manufacturer.

Daniel Fritz: With other supply chains it is similar. People want to buy organic food – how do you know it is bio? With blockchain, we can guarantee the provenance of a product and remove or reduce counterfeits from the supply chain. This benefits the industry and the patients.

Marco Cuomo: Speaking of patients: It is the holy grail to bring patients in control of their data. Today the data sits in the different silos, with the hospitals, with physicians for example. With the blockchain, we think there is the potential to open that up so that patients can decide who sees my data.

Where do you see other advantages of Blockchain based healthcare?

Marco Cuomo: Our CEO Vas Narasimhan has the vision to create a medicine based on data only, from real world evidence. Blockchain can help to track and trace the data to guarantee its proper provenance. Another opportunity are data marketplaces where you can offer your data to pharmaceutical companies and researchers. Blockchain could help with that. Where normally it would take time to build up the trust for such an exchange of very sensible and valuable data, there is no need for that with blockchain. Novartis hopes that we can use this data to create new medicine in the future. We are also looking into third party risk management.
How can we make sure that our suppliers comply to our labor and safety rules? Why should we have the same audit ten times a year instead of once? Why should these assessments not be owned by the supplier – if we are guaranteed that the supplier is not manipulating them?

You started two years ago as a small group. Where are you now?

Marco Cuomo: We realized that we need to define certain standards to lay the infrastructural ground for Blockchain in healthcare. That is why we submitted the project “Blockchain enabled healthcare” with the Innovative Medicine Initiative where Novartis is already heavily engaged with more than 100 projects. We convinced eight other companies to join: J&J, Bayer, Sanofi, AstraZeneca, UCB, Pfizer, Novo Nordisk, and AbbVie are part of it. The money comes half from the industry, the other half is from the EU, in total 18 million Euro for three years. Applications for the consortium that should include hospitals, labs, patients, SME and universities to work with us closed in October. After that, we will form a project together and start with it late next year.

What is blockchain enabled healthcare about?

Marco Cuomo: The main goal is to define standards to create a governance body that will last longer than the project itself. Like the W3C, the World Wide Web Consortium that is defining technical standards of the web, we hope to be the same for Blockchain in healthcare. Take the internet – it also needed someone who defined some standards so everyone could build on that. The same will happen here, hopefully. Imagine if Novartis was to implement their own blockchain and has to convince thousands of suppliers to use it. If the next company does the same, end-to-end product tracking becomes impossible for the parties involved. Why should doctors use our system or the other one? Also, the patient journey does not only include pills from Novartis. You need a standard.

How easy was it to convince the other companies to come on board?

Daniel Fritz: Some of the companies we asked jumped on board immediately. Others needed to understand our vision in more detail. So we had a lot of talks which were very positive as we were able to establish a high level of trust and collaboration within the consortium, which is really what blockchain is about.

In which ways did it help to be in Basel to start this journey?

Marco Cuomo: It started here and Novartis is leading it. All the companies and the academia we talked to form the initial approach to the program are close. It also helps to have a CEO who strongly supports digital initiatives and a CDO who sees the potential.

Daniel Fritz: Momentum for blockchain in healthcare is growing in Basel, in Novartis, and globally. It will benefit patients and the industry, but we have a lot of hard work in the consortium and with public partners to get there.

About

Marco Cuomo is Manager of Applied Technology Innovation and a Senior Digital Solutions Architect with Novartis. He started with Novartis in 2005 as a Business Informatics Engineer and gained a Bachelor of Science in Business Administration.

Daniel Fritz works as the Supply Chain Domain Architect at Novartis. Before that he was an engineer officer with the US Army and a Materials Manager. He studied at the US Military Academy at West Point and gained a Master of Business Administration from Duke University.

report Invest in Basel region

Basler Kantonalbank launches innovation subsidiary

10.01.2019

report Life Sciences

Unitelabs automating lab work

08.01.2019

report BaselArea.swiss

Expats like Basel best

23.11.2018

Expats find Basel to be the best city in Switzerland, according to a study published by InterNations. Six Swiss cities were analyzed as part of its latest Expat City Ranking.

Basel, Zug, Lausanne, Geneva, Zurich and Bern are among the 72 cities around the world analyzed in the Expat Insider City Ranking 2018, published by InterNations. The expat organization also interviewed over 18,000 expats to produce its latest ranking.

Among the six Swiss cities, Basel was ranked the most popular by expats, coming 22nd in the overall ranking. Zug was the second most popular Swiss city, coming in 23rd, while Lausanne (44), Geneva (56), Zurich (57) and Bern (61) all placed in the lower half of the ranking.

Tapei came in first place overall, followed by Singapore, Manama, Ho Chi Minh City, Bangkok and Kuala Lumpur. Aachen was the highest ranked European city coming in seventh, while Rome, Jeddah and Riyadh were the three lowest ranked cities.   

According to an article by swissinfo, Basel scored particularly well among expats for its economic climate, coming in fifth place in this category. The city on the Rhine came in 10th for quality of life, with expats praising its transport system, and 28th for personal finances and housing. In contrast, 32 per cent said they do not feel at home (compared with 23 per cent worldwide), and 54 per cent said that it is difficult to forge new friendships (compared with 34 per cent worldwide).

report

Infographic: The Basel Biotech & Pharma Ecosystem

07.01.2019

report Innovation

Centre for abdominal disorders opens in Basel

07.01.2019

report BaselArea.swiss

Roivant raised USD 200 million, now valued at USD 7 billion

14.11.2018

The Basel-based pharmaceutical company Roivant Sciences has raised USD 200 million in a funding round. As a result, the company is now valued at an estimated USD 7 billion.

Roivant Sciences reported in a press release that all existing institutional shareholders participated in the latest funding round. The Basel pharma company also attracted a number of new investors, including NovaQuest Capital Management and RTW Investments. These new investors made up the majority of this latest funding drive, in which Roivant raised USD 200 million. The round has not yet finished and is only expected to close in early December. According to the press release, this latest financing puts the value of Roivant Sciences at approximately USD 7 billion.

Since the previous Roivant funding round last year, the number of therapies in development has grown from 14 to 34 and the company has increased its subsidiary “Vants” from six to 14. There has also been growth in employee numbers across Roivant and the Vants, from under 350 to more than 750. In addition, the Roivant subsidiary Enzyvant initiated a biologics licence application for a regenerative therapy to the U.S. Food and Drug Administration (FDA).

For 2019, the company anticipates topline data from six Phase 3 clinical trials. Roivant Health also intends to launch new Vants next year. This subsidiary was founded in June to develop companies that bring innovative medicines to emerging markets and improve the process of developing and commercialising new medicines through the application of technology. Sales are also expected to grow for Datavant, founded in autumn 2017 as a subsidiary that uses artificial intelligence in data analysis to improve the clinical trial process and accelerate drug development.

Roivant Sciences and its subsidiaries are supported by BaselArea.swiss as they establish themselves in Basel.

Cookies

BaselArea.swiss uses cookies to ensure you get the best service on our website.
By continuing to browse the site, you are agreeing to the use of cookies.

Ok